A Retrospective Review of DEXTENZA 0.4 mg inseRt Following Corneal Transplant or Cataract Surgery

NCT04975971 · clinicaltrials.gov ↗

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Anterior Chamber Inflammation
Ocular Pain
Corneal Edema
Corneal Defect
Penetrating KeratoPlasty
Nuclear Cataract
Cortical Cataract
Cataract Senile

Interventions

DRUG: Dextenza 0.4Mg Ophthalmic Insert

Sponsor

Nicole Fram M.D.